ABfinity™ antibody characteristics include:
• Validation in Western blot and indirect ELISA
• Superior lot-to-lot consistency
• Extremely high specificity and sensitivity
• Recombinant rabbit monoclonal antibody
• Specific for LMO2
LMO2, (LIM domain only protein 2) is an important transcriptional regulator of erythropoiesis and vascular remodeling (1, 2) LMO2 plays a role as an adaptor protein, and assist in the assembly of multimeric transcription factor complexes. LMO2 encodes a small protein comprising two zinc-binding LIM-domains and becomes activated after chromosomal translocations in specific T cells (3).
Exceptional Consistency Saves You Time and Money
ABfinity™ antibodies are produced by transfection of mammalian cells with heavy and light chain antibody cDNAs. This provides you with the highest consistency between lots, eliminating the need to revalidate your assays for each lot.
High Specificity Means More Reliable Data
The proprietary recombinant technology employed in the production of ABfinity™ antibodies means you are assured of the greatest degree of reliability. Staining of nonspecific proteins is virtually eliminated while very high sensitivity is achieved. Life Technologies has validated this antibody in Western blotting.
High Sensitivity Lets You Detect Low Levels of Target Protein
ABfinity™ antibodies demonstrate much higher sensitivity than ordinary antibodies. Proteins expressed in low levels can be detected with high specificity allowing you to use less of your precious samples than with ordinary antibodies.
Recombinant Rabbit IgG – Use Like Any Other IgG Antibody
As with traditional IgG antibodies, gel electrophoresis of ABfinity™ antibodies produces a 150 kDa band under non-reducing conditions and 50 kDa and 25 kDa bands under reducing conditions.
For Research Use Only. Not intended for any animal or human therapeutic or diagnostic use.
Related Links:
Learn more about the superior performance of ABfinity™ recombinant monoclonal antibodies.
See Life Technologies' full line of ABfinity™ recombinant monoclonal antibodies.
References:
- Brandt SJ, Kaury MJ. Regulation of LMO2 mRNA and protein expression in erythroid differentiation. Haematologica 2009 Apr 94;4: 447-448
- Nam CH, Rabbitts TH. The role of LMO2 in development and in T Cell Leukemia after chromosomal translocation or retroviral insertion. Mol. Therapy 2006 13: 15-25
- Yamada Y, Pannell R, Forster A, Rabbitts TH. The LIM-domain protein Lmo2 is a key regulator of tumor angiogenesis: a new anti-angiogenesis drug target. Oncogene 2002 Feb 21;21(9): 1309-1315
